CoChat

Germline Analysis from Tumor–Germline Sequencing Dyads to Identify Clinically Actionable Secondary Findings

Open access
Seifert, Bryce A., O'Daniel, Julianne M., Amin, Krunal, Marchuk, Daniel S., Patel, Nirali M., Parker, Joel S., Hoyle, Alan P., Mose, Lisle E., Marron, Andrew, Hayward, Michele C., Bizon, Christopher, Wilhelmsen, Kirk C., Evans, James P., Earp, H. Shelton, Sharpless, Norman E., Hayes, D. Neil, Berg, Jonathan S. · 2016 · Clinical Cancer Research
Cited by 95

The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.

Abstract

Purpose: To evaluate germline variants in hereditary cancer susceptibility genes among unselected cancer patients undergoing tumor–germline sequencing. Experimental Design: Germline sequence data from 439 individuals undergoing tumor–germline dyad sequencing through the LCCC1108/UNCseq™ (NCT01457196) study were analyzed for genetic variants in 36 hereditary cancer susceptibility genes. These variants were analyzed as an exploratory research study to determine whether pathogenic variants exist within the germline of patients undergoing tumor–germline sequencing. Patients were unselected with respect to indicators of hereditary cancer predisposition. Results: Variants indicative of hereditary cancer predisposition were identified in 19 (4.3%) patients. For about half (10/19), these findings represent new diagnostic information with potentially important implications for the patient and their family. The others were previously identified through clinical genetic evaluation secondary to suspicion of a hereditary cancer predisposition. Genes with pathogenic variants included ATM, BRCA1, BRCA2, CDKN2A, and CHEK2. In contrast, a substantial proportion of patients (178, 40.5%) had Variants of Uncertain Significance (VUS), 24 of which had VUS in genes pertinent to the presenting cancer. Another 143 had VUS in other hereditary cancer genes, and 11 had VUS in both pertinent and nonpertinent genes. Conclusions: Germline analysis in tumor–germline sequencing dyads will occasionally reveal significant germline findings that were clinically occult, which could be beneficial for patients and their families. However, given the low yield for unexpected germline variation and the large proportion of patients with VUS results, analysis and return of germline results should adhere to guidelines for secondary findings rather than diagnostic hereditary cancer testing. Clin Cancer Res; 22(16); 4087–94. ©2016 AACR. See related commentary by Mandelker, p. 3987

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1158/1078-0432.ccr-16-0015

Cites

5 of 5 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 5 references

Cited by

See all 95

Metadata

Authors
Seifert, B. A., O'Daniel, J. M., Amin, K., Marchuk, D. S., Patel, N. M., Parker, J. S., Hoyle, A. P., Mose, L. E., Marron, A., Hayward, M. C., Bizon, C., Wilhelmsen, K. C., Evans, J. P., Earp, H. S., Sharpless, N. E., Hayes, D. N., & Berg, J. S.
Venue
Clinical Cancer Research
Published
2016-08-14
Volume
22
Issue
16
Pages
4087-4094
ISSN
  • 1078-0432 (ISSN-L)
  • 1557-3265
OpenAlex
W2340353572
Cited by
95
References
5
FWCI
6.60
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Germline Analysis from Tumor–Germline Sequencing Dyads to Identify Clinically Actionable Secondary Findings. https://app.cochat.ai/papers/10.1158/1078-0432.ccr-16-0015
The paper
Seifert, B. A., O'Daniel, J. M., Amin, K., Marchuk, D. S., Patel, N. M., Parker, J. S., Hoyle, A. P., Mose, L. E., Marron, A., Hayward, M. C., Bizon, C., Wilhelmsen, K. C., Evans, J. P., Earp, H. S., Sharpless, N. E., Hayes, D. N., & Berg, J. S. (2016). Germline Analysis from Tumor–Germline Sequencing Dyads to Identify Clinically Actionable Secondary Findings. Clinical Cancer Research. https://doi.org/10.1158/1078-0432.ccr-16-0015

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.